Global Blood Therapeutics (GBT) Data 'Exceeded Our High Expectations' - Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St set to open higher as investors weigh earnings; PayPal jumps
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices rise as hostilities worsen in the Middle East
- ASML capacity upgrade soothes AI chip bottleneck fears
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Kosovo bans Serb minister over ethnic cleansing remarks
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
Global Blood Therapeutics (GBT) Gains on Positive Results from Ongoing Sickle Cell Drug Trial
June 10, 2016 9:07 AM EDTGlobal Blood Therapeutics (NASDAQ: GBT) is gaining 21% pre-open trade after the company... More
Global Blood Therapeutics (GBT) Announces New Results from Ongoing Phase 1/2 GBT440-001 Study in Sickle Cell Disease
June 10, 2016 8:01 AM EDTGlobal Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced new results from its ongoing Phase 1/2 GBT440-001 study in sickle cell disease (SCD) that further support the company's plans to develop GBT440 as a potential disease-modifying therapy for SCD. The data being presented today at the European Hematology Association's (EHA) 21st Congress in Copenhagen include a poster presentation of... More
